Other

COI declarations and off-label drug use

Conflict-of-interest statements made by physicians and scientists in their medical journal articles after they had been allegedly paid by pharmaceutical manufacturers as part of off-label marketing programs are often inadequate, ...

Medications

Vandetanib in thyroid cancer: Added benefit not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute ...

Medications

3Qs: Analyzing why sudden drug shortages occur

Drug manufacturers and the Food and Drug Administration (FDA) scrambled earlier this month to address a sudden shortage of methotrexate, a 60-year-old drug that treats children with severe cases of leukemia and sarcoma. Graham ...

Medications

Drug makers engage in 'co-opetition' through drug middlemen

Prescription drug consumers confounded by the cost of their medications can get a peek behind the curtain thanks to new Washington University in St. Louis research into the complex "co-opetition"—cooperation and competition—among ...

page 9 from 20